1. John Maraganore

    0 Comments Leave a Comment

    1-3 of 3

    1. Mentioned In 3 Articles

    2. Chroma Medicine Strengthens Leadership with Addition of George Golumbeski to Board of Directors and John Maraganore as Strategic Advisor

      Explore PR Newswire BoardMoves
      Chroma Medicine Strengthens Leadership with Addition of George Golumbeski to Board of Directors and John Maraganore as Strategic Advisor
      Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering epigenetic editing therapeutics, today announced the appointment ofGeorge Golumbeski, Ph.D., former Executive Vice President of Business Development at Celgene, as an Independent Director andJohn Maraganore, Ph.D., former CEO of Alnylam, as a Strategic Advisor...
      Read Full Article
      Mentions: Leadership Independent Director Celgene
    5. 1-3 of 3
  1. Search:

  2. Categories

    1. BoardProspects Features:

      Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content

  3. Related Topics

    1. Alnylam Elects Amy Schulman to its Board of Directors
      7 articles also mentioned Board of Directors
    2. Alnylam Elects Michael W. Bonney to Its Board of Directors
      5 articles also mentioned Board
    3. bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors
      2 articles also mentioned acquisition

  4. Quotes

    1. Dr. Westphal and I have worked together closely for nearly 15 years on several important companies, including Alnylam.
      In Flex Pharma CEO Christoph Westphal, M.D., Ph.D., Joins BIO Emerging Companies Governing Board
    2. Mike is a recognized leader in the development and growth of successful, commercial-stage biopharmaceutical companies. This expertise will be very valuable to our Board, as we continue to build Alnylam as a leading biotechnology company, ultimately commercializing products from our pipeline of RNAi therapeutics.
      In Alnylam Elects Michael W. Bonney to Its Board of Directors
    3. Amy is a recognized leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our Board as we continue to build Alnylam as a leading biotechnology company. As the former General Counsel at Pfizer, Amy also brings deep legal expertise to our Board.
      In Alnylam Elects Amy Schulman to its Board of Directors